Photocure ASA · OSL:PHO
Photocure ASA — Shareholder Meeting (June 2020)
13 slides from Photocure ASA's shareholder meeting presentation, Jun 10, 2020
Slide 1: Photocure ASA AGM - State of the Business
PHOTOCURE ASA AGM - STATE OF THE BUSINESS 10 June 2020 Daniel Schneider, President and CEO
Slide 2: Our mission is to deliver transformative solutions for bladder cancer patients
OUR MISSION IS TO DELIVER TRANSFORMATIVE SOLUTIONS WHICH IMPROVE THE LIVES OF BLADDER CANCER PATIENTS Photocure’s four step strategy will deliver our mission 1 2 3 4 Accelerate Expand Acquire Transform • Drive the breadth •A Generate sales in • Partner and in- • Build a global and depth of new geogr
Slide 3: Past year highlights: contributing to Photocure strategy implementation
PAST YEAR HIGHLIGHTS: CONTRIBUTING TO PHOTOCURE STRATEGY IMPLEMENTATION Regaining worldwide rights to Hexvix • Expected to be EBITDA1 accretive from full-year 2021 • After transition year targeting approximately 30% annual revenue growth in current Ipsen territories Partnership highlights: Cevira De
Slide 4: Hexvix/Cysview – key enablers in place and ready for growth
HEXVIX®/CYSVIEW® – KEY ENABLERS IN PLACE AND READY FOR GROWTH WE WILL GET THE 5 KEY ENABLERS IN PLACE FOR EU Penetration POSITION IN THE LIFE CYCLE KEY SUCCESS FACTORS 100% Approval Surgical & surveillance 75% Acceptance Major & local guidelines Denmark Permanent and 50% Access favorable reimburseme
Slide 5: Large untapped potential in the EUR 150 million European market
LARGE UNTAPPED POTENTIAL IN THE EUR 150 MILL EUROPEAN MARKET (CURRENT EU PENETRATION (EXCEPT DACH) <5% WITH OPPORTUNITY TO REACH NORDIC LEVEL OF 40%) Europe U.S. Europe: 165,000 new US: 82,500 new cases NORDICS cases and more than and more than 18,000 40% penetration 50,000 deaths deaths annually1 a
Slide 6: U.S. accelerated momentum: explosive and sustainable growth
U.S. ACCELERATED MOMENTUM EXPLOSIVE & SUSTAINABLE GROWTH IN THE PAST 24 MONTHS 98 704 63 807 42 607 30 465 23 017 12 278 8 249 4 921 2012 2013 2014 2015 2016 2017 2018 2019 U.S. (1000 NOK) 6
Slide 7: Recent quarters' installation fuels future growth
U.S. ACCELERATED MOMENTUM: RECENT 8 QUARTERS’ INSTALLATION FUELS FUTURE GROWTH! Annual New Installations Cumulative install base continues strong trend * * Tower placements by year 7 *2012 – 17 of the 23 installations were converted clinical sites upon Cysview approval
Slide 8: Photocure sustainability report
Photocure sustainability report
Slide 9: 2019 Sustainability / ESG report: doing things the right way
2019 SUSTAINABILITY / ESG REPORT: DOING THINGS THE RIGHT WAY • Photocure has recently prepared the company’s first sustainability report for 2019, Investors/ Suppliers in accordance with GRI and Euronext Shareholders reporting guidelines. Customers/ Government • The report covers sustainability topi
Slide 10: Photocure's material topics
PHOTOCURE’S MATERIAL TOPICS Product quality Supply chain Working Business ethics Data protection and safety responsibility environment and transparency and IT security • Quality system • Supplier follow-up • Workforce • Systems and governance • Systems and policies • No. of incidents 2019: 0 • Suppl
Slide 11: Summary and Outlook
Summary and Outlook — ——
Slide 12: Optimistic to rebound from COVID-19 impact in H2
OPTIMISTIC TO REBOUND FROM COVID-19 IMPACT IN H2 BLCTM with Hexvix®/Cysview® can play an integral part in this situation: postponed procedures* do not postpone aggressive cancer progression • Patient safety through better detection of bladder cancer tumors, in spite of the potential longer check-up
Slide 13: Aspiration: creating the leading bladder cancer company
ASPIRATION: CREATING THE LEADING BLADDER CANCER COMPANY 1 2 3 4 Accelerate Expand Acquire Transform • Drive the breadth •A Generate sales in • Partner and in- • Build a global and depth of new geographies license synergistic Bladder Cancer Hexvix/Cysview assets to Company usage in key •B Enhance the